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 INTRODUCTION 
 Community-directed treatment with ivermectin is the most 
cost-effective and sustainable strategy to control onchocercia-
sis. 1 However, the participation of persons in distribution cam-
paigns is limited in some areas because of the occurrence of 
rare but sometimes fatal serious adverse events (SAEs). The 
worst presentation of these events involves encephalopathy 
with neurologic disorders and coma. 2 The main risk factor for 
these SAEs is the presence of a high  Loa loa microfilaremia. 3 
Loiasis is highly endemic in rainforest areas of central Africa 
and its main clinical manifestations include migrating angioe-
dema known as Calabar swelling, pruritus, and passage of the 
adult worm under the conjunctiva. Although the pathophysi-
ology of the SAEs is not fully understood, it is known that 
ivermectin has a steady effect on  L. loa microfilaremia, and 
clinical observations suggest that the neurologic disorders 
may be caused by obstruction of brain capillaries by paralyzed 
 L. loa microfilaria (mf), or penetration into the central ner-
vous system of mf trying to escape the effects of ivermectin. 4 , 5 
The risk of post-ivermectin encephalopathy is significantly 
increased when the  L. loa count exceeds 30,000 mf/mL, and 
then increases exponentially with microfilaremia. 3 
 One way of preventing SAEs would be to progressively 
reduce the  L. loa microfilaremia below the risk level before 
treating with ivermectin. To achieve this reduction, a treatment 
that eliminates  L. loa mf and that can easily be distributed on a 
large scale needs to be identified. Albendazole given at a dose 
of 200 mg twice a day for 21 days may reduce  L. loa microfila-
remia by 80% after 6 months, 6 but this regimen is logistically 
challenging for mass treatment programs. Unfortunately, when 
this drug is given in a single dose of 600 mg, 400 mg once a day 
for 3 days, or 400 mg twice a day for 3 days, it has little or no 
effect on  L. loa microfilaremia. 7 – 9 Use of ivermectin at low sin-
gle doses (25–50 μg/kg) do not give significantly different results 
from that observed with a standard dose (150 μg/kg). 10 , 11 
 A number of studies have been conducted to evaluate the 
effects of antimalarial drugs on filariae. We have undertaken an 
exhaustive literature review on the topic, the results for which 
are presented in the form of detailed supplementary mate-
rial ( Supplementary Tables 1 – 6 , available at  www.ajtmh.org ). 
The drugs tested included aryl-amino-alcohols (quinine, 
mefloquine), 4-aminoquinolines (chloroquine, amodiaquine, 
quinacrine), and primaquine. Different drugs showed variable 
efficacies against different filarial species (see Supplementary 
 Tables 1 – 6 and Discussion for details). Results of  in vivo tri-
als of chloroquine and amodiaquine are of particular interest. 
Chloroquine resulted in a marked decrease in  Onchocerca 
volvulus microfilarial loads, and had a macrofilaricidal effect 
when injected into the onchocercal nodules, but not when 
administered orally. 12 – 14 Amodiaquine showed a macrofila-
ricidal effect on  Wuchereria bancrofti in one patient treated 
with a high dose (2,400 mg over 4 days). 15 
 Artemisinins are effective against  Plasmodium spp. and 
various trematodes such as  Schistosoma mansoni and  Fasciola 
hepatica . 16 To the best of our knowledge, these drugs have 
been tested only once against filariae. Artemisinin, when given 
at a dose of 100 mg/kg/day for 5 days in the rodent  Meriones 
unguiculatus transplanted with adult  Acanthocheilonema 
vitae and  Brugia malayi , appeared to have little effect on the 
parasites. 17 However, it is worth further exploring antifilarial 
activity of artemisinins because their mode of action against 
sensitive helminths is still not well known. 18 , 19 
 Because of results of trials of chloroquine 12 – 14 and amodi-
aquine 15 on filariae, we selected these two compounds as good 
candidates for the present trial. Quinine has never been tested 
 in vivo against filariae, but was selected because of its moder-
ate effect  in vitro on  B. pahangi . 20 Artesunate was chosen for 
the reason given in the preceding paragraph. 
 Safety considerations were also taken into account to select 
the drugs to be tested. This criterion was most important 
because should a compound show a significant effect on  L. loa , 
then mass treatment using this drug may be used to reduce the 
 L. loa microfilaremias in the population before distributing 
ivermectin. The main adverse reactions after quinine treatment 
is a complex of symptoms, known as cinchonism, which resolve 
with discontinuation of treatment. 21 Quinine may induce seri-
ous adverse events such as blackwater fever or hypoglycemia. 
However, blackwater fever occurs mainly in persons with no 
or low immunity against malaria, which is exceptional in per-
sons from malaria-endemic areas, 22 and hypoglycemia occurs 
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in patients with severe malaria 23 or after high doses of qui-
nine. 24 Standard doses of chloroquine are generally well tol-
erated. 21 Extrapyramidal symptoms and psychiatric reactions 
have been reported during chloroquine treatment but are 
exceptional. 25 A study conducted in the United Kingdom 
indicated that amodiaquine may induce agranulocytosis and 
hepatitis with fatality rates of 1/31,300 and 1/15,650, respec-
tively. 26 , 27 However, because the combination amodiaquine 
plus artesunate is a first-line therapy for treatment of patients 
with uncomplicated malaria in Cameroon, we decided to keep 
amodiaquine in our trial. Lastly, artesunate, as are other deriv-
atives of artemisinin, is remarkably safe and well tolerated. 21 
Following the above considerations, we decided to assess the 
effect of quinine, chloroquine, amodiaquine, and artesunate on 
 L. loa microfilaremia. 
 PATIENTS AND METHODS 
 Study area and patient selection.  The trial was conducted 
in six villages 40–80 km east of Yaoundé, in the Mefou and 
Afamba Division, Center Region, Cameroon. Because loiasis 
is highly endemic and onchocerciasis is hypoendemic in the 
area, 11 no mass ivermectin distribution has ever been imple-
mented in this region. 
 The first phase of the trial consisted of identification and 
recruitment of microfilaremic persons. Information on the 
objectives and procedures of the survey was given to the pop-
ulation of each selected village. Persons ≥ 15 years of age who 
volunteered to participate in the study underwent a parasito-
logic examination. Blood was collected between 11:00  am and 
3:00  pm by fingerprick and a calibrated thick blood film (CTBF) 
of 50 μL was prepared for each volunteer. Slides were stained 
using Giemsa and  L. loa mf were counted under a microscope. 
Subjects harboring ≥ 200  L. loa mf/mL and who signed an 
informed consent form underwent a clinical examination and 
were interviewed regarding their medical history. Those per-
sons who had received antifilarial treatment during the previ-
ous year, persons with epilepsy, and pregnant or breastfeeding 
women were excluded from the trial. All remaining persons, 
when in good health, were enrolled in the trial. 
 Study design, randomization, treatment, and follow-up. 
 This was an open trial. All patients enrolled were stratified 
according to their  L. loa microfilaremia by using the following 
classes: 200–7,999, 8,000–30,000, and > 30,000 mf/mL). Persons 
were then randomly allocated, for each stratum, into five 
treatment groups: one for each of the four antimalarial drugs 
tested and a control group. 
 On the first day (D0), a CTBF was prepared for every 
patient by using the same procedure as in the preliminary sur-
vey to re-assess their baseline  L. loa microfilaremia immedi-
ately before treatment. Patients treated with quinine received 
600 mg twice a day for 5 days, those treated with chloroquine 
received 600 mg once a day for 3 days, those treated with amo-
diaquine received 800 mg once a day for 3 days, and those 
treated with artesunate received 200 mg once a day for 3 days. 
We used generic quinine and chloroquine tablets and Falcimon 
kits ® (Cipla, Mumbai, India) containing separate amodiaquine 
and artesunate tablets. Patients in the control group received 
a single dose of iron-folic acid (four tablets each containing 
65 mg of iron and 0.25 mg of folic acid). Treatments were 
administered under the direct observation of investigators. 
Surveillance of potential adverse events was conducted on a 
daily basis during the treatment period and then at each sub-
sequent visit. 
 Loa loa microfilaremia was monitored by examination of 
CTBF on days 3, 7, 15, 30, 60, and 90. To reduce the effect of 
daytime variability in microfilaremia, 28 the samples were col-
lected from each patient at approximately the same time as it 
was collected on D0. The slides were examined independently 
by two microscopists in a blind manner relative to treatment, 
and the microfilaremia counts were considered valid when the 
two results differed by less than 10%. The average value was 
used for statistical analyses. 
 Statistical analyses.  Microfilaremia was compared between 
the five groups at each examination round by using the Kruskal-
Wallis test. To compare the longitudinal trend in microfilaremia 
between treatments, we performed a regression analysis using 
a linear mixed-effects model, which adequately handles cross-
sectional measures taken repeatedly on the same persons. The 
outcome variable was the  L. loa microfilaremia. The regressors 
were the treatment group and the day of sampling, which were 
entered in the model as main factors and as interaction terms. 
To account for non-normality of microfilarial load distribution, 
these loads were logarithmically transformed. Intra-individual 
correlation between consecutive measures and potential inter-
individual variation around the average trend were accounted 
for by a random effect set at the subject level. Analyses were 
performed using Stata software version 10.0 (Stata Corp., 
College Station, TX). 
 Ethical agreement.  The trial was reviewed and approved by 
the National Ethics Committee of Cameroon. Administrative 
authorization was provided by the Cameroon Ministry of 
Public Health. All patients benefited from general health 
checks during the follow-up. 
 RESULTS 
 Overall, 901 persons were screened during the preliminary 
survey. The prevalence of  L. loa microfilaremia was 27.1%. 
A total of 142 persons were eligible for the trial (microfilare-
mia ≥ 200 mf/mL) and allocated into the five groups. Only 98 
patients (50 female patients and 48 male patients) were pres-
ent on D0 and finally enrolled in the trial. The mean age of the 
study population was 52.6 years (range = 14–80 years). 
 All patients included in the trial received the full treat-
ment, and no serious adverse events were reported. All events 
recorded were mild, and related mostly to amodiaquine, chlo-
roquine, and quinine. In the amodiaquine group, six patients 
had asthenia, one had a headache, one had anorexia and one 
had ocular itching. Among persons treated with quinine, three 
reported asthenia, one reported dizziness, and one reported tin-
nitus. In the chloroquine group, three patients had itching, one 
had asthenia, one had tinnitus, and one had insomnia. Among 
the persons treated with artesunate, two reported asthenia 
and one reported itching. All adverse events spontaneously 
regressed within 24–48 hours after the last dose of drug. 
 At D0, microfilaremia levels were similar in the different 
treatment groups. No statistically significant difference was 
observed between the groups at any of the subsequent exami-
nations ( Table 1 ). Individual changes with time in each treat-
ment group are shown in  Figure 1 . No significant decrease in 
microfilaremia was observed in any of the groups during the 
90-day follow-up. This finding was confirmed by results of the 
mixed-effects linear model ( Table 2 ). 
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 DISCUSSION 
 To the best of our knowledge, the present trial is the first 
ever conducted to evaluate the effect of antimalarial drugs on 
 L. loa . We included patients harboring a wide range of  L. loa 
microfilaremias, including some who had less than 8,000 mf/mL, 
and thus would not be at risk for developing marked or seri-
ous adverse events after ivermectin treatment. Because of 
the initial stratification procedure, the geometric mean  L. loa 
microfilaremia did not differ significantly between the groups 
before treatment. 
 The drug regimens we used were not the exact recommen-
dations for the treatment of patients with malaria but were 
adapted so as to be applicable (in terms of number of doses 
received per day and numbers of days) as part of a mass treat-
ment regimen. The time points of follow-up were chosen so as 
to be able to detect either a rapid decrease in the microfilarial 
count (from D1 to D15), as recorded in the trials of chloro-
quine on  O. volvulus , 12 , 13 or a more progressive effect (on D30 
and D90), as observed in one patient infected with  W. ban-
crofti treated with amodiaquine. 15 The examinations on D90 
would have enabled us to detect an effect limited to the adult 
worms, whether a macrofilaricidal effect or an interruption of 
the release of new mf. Knowing that the lifespan of  Loa mf 
is approximately 6–12 months, 29 the microfilarial load on D90 
would be reduced by 25–50%. 
 In light of our objective (to bring about a slow decrease in 
the  L. loa microfilaremia), even a moderate or delayed effect 
would have been desirable. Unfortunately, our results show 
that none of the four antimalarial regimens tested has a signif-
icant effect on  L. loa microfilaremia. The fact that no decrease 
was recorded at any time point suggests that the drugs at the 
doses administered were inactive on mf and adult worms. 
 Given the promising results previously obtained with chlo-
roquine, its inefficacy against  L. loa is particularly disap-
pointing. Chloroquine was first tested  in vitro against mf and 
adults of  O. volvulus and  O. gutturosa , 20 , 30 – 35 and then  in vivo 
in onchocerciasis patients. 12 – 14 This drug, when given  per os , 
appeared to bring about a marked decrease in microfilarial 
loads and had a macrofilaricidal effect when injected into the 
onchocercal nodules but not when administered orally. In addi-
tion, it was shown that after oral treatment, adult  O. volvulus 
accumulated the drug to high concentrations. 36 Chloroquine 
was also tested  in vitro against  B. pahangi ,  B. patei ,  Dirofilaria 
immitis and  A. vitae , 20 , 33 , 34 , 37 and  in vivo against  D. immitis . 38 
It was less effective or less active on these species than on 
 Onchocerca spp. 
 The discrepancy in the results obtained for  O. volvulus and 
 L. loa may be caused by differences in the localization of para-
sites, and thus in the level of exposure to the drug.  Onchocerca 
volvulus mf live in the dermis, whereas  L. loa mf circulate in 
the bloodstream. With regard to the adult stages,  O. volvu-
lus macrofilaria are located in subcutaneous or deep nodules, 
whereas those of  L. loa are found in the connective tissue 
under the skin and the fascial layers overlying the somatic 
muscles. Because chloroquine concentrations observed in the 
skin are much higher than those in plasma, 36 , 39 one may assume 
that for a given oral dose of chloroquine mf of  O. volvulus are 
more exposed to the drug than those of  L. loa . With regard 
to adult worms, it has been shown that after oral treatment, 
 O. volvulus accumulates chloroquine to concentrations more 
than 100 times higher than that measured in the skin or the 
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nodular tissue around the adult worms. 36 Despite this finding, 
no macrofilaricidal effect was observed after oral chloroquine 
treatment, 13 and adult  O. volvulus were killed only when the 
drug was injected into the nodule. 14 Thus, high concentrations 
are required to obtain a macrofilaricidal effect, which may also 
be true for  L. loa , whose adults are often located in poorly vas-
cularized tissues. 
 The lack of effect of amodiaquine on  L. loa is also disap-
pointing. The possible antifilarial activity of amodiaquine has 
also been studied  in vitro against  B. pahangi 20 and  Breinlia bool-
iati 40 and  in vivo against  O. volvulus , 41  Wuchereria bancrofti , 15 , 42 
and  Litomosoides carinii . 43 – 45 A macrofilaricidal effect was 
reported for all species tested, except for  O. volvulus (see sup-
plementary material for details). With regard to  W. bancrofti , 
a progressive decrease in microfilaremia (from 114 mf/mL on 
D0 to 16 mf/mL on D90) was observed in a patient treated 
with a dose (2,400 mg over 4 days) similar to that administered 
as part of the present trial. 15 We have no explanation for the 
absence of an effect of amodiaquine on  L. loa . 
 The lack of an effect obtained with artesunate confirms pre-
vious observations in animal models, which showed little anti-
filarial effect for this drug. 17 This finding may be related to the 
fact that artesunate has a shorter life-time (less than one hour) 
than chloroquine or amodiquine. 
 Other antimalarial compounds that had been tested against 
filariae were not used in the present trial because of safety 
reasons or because they were not available commercially. 
Quinacrine showed no effect against  O. volvulus mf  in vivo , 46 
but had a moderate effect against  B. pahangi adult females  in 
vitro . 20 Attempts to increase the antifilarial activity of 4-amin-
oquinolines were made by synthesizing derivatives, 40 , 47 , 48 but 
the results were disappointing. The activity of mefloquine was 
evaluated  in vitro against  B. patei mf and against adult stages 
of  O. gutturosa , 49  B. malayi , and  B. patei . 37 The drug seemed to 
have a paralyzing effect but for the latter two species this effect 
disappeared when fetal calf serum and human serum were 
added to the medium. Lastly, primaquine was shown to have a 
marked effect against  B. pahangi adult worms  in vitro 20 and a 
delayed effect on  W. bancrofti microfilaremia in humans. 50 
 Despite the disappointing results of the present trial, it 
would be worth investigating the modes of action of antima-
larial drugs against filariae. The detailed modes of action of 
quinoline-containing drugs on  Plasmodium spp. seem to differ 
according to the compounds, but in each case they rely on the 
mechanisms related to hemoglobin digestion. 51 , 52 Interference 
with hemozoin formation also explains at least partly the 
action of antimalarial drugs on  Schistosoma spp. 53 – 57 However, 
what occurs in blood-feeding helminths such as  Schistosoma 
 Figure 1.  Individual follow-up of  Loa loa microfilaremia in the five treatment groups (quinine, 1,200 mg/day for 5 days; chloroquine, 600 mg/day 
for 3 days; amodiaquine, 800 mg/day for 3 days; artesunate, 200 mg/day for 3 days; control group, persons receiving iron-folic acid tablets). Thick 
lines represent the geometric mean numbers of  Loa loa microfilaria per milliliter of blood. 
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spp. may not be true for filariae. Even if iron was found in the 
intestinal epithelial cells of adult  Onchocerca sp., 58 – 60 and blood 
feeding has been observed in young adult  L. sigmodontis , 61 it is 
thought that filariae feed mainly through the body wall. 62 Thus, 
the antifilarial activity of quinoline drugs probably results from 
mechanisms different from those occurring in other sensitive 
parasites. To our knowledge, this activity has been investigated 
only by VandeWaa and others, 63 who evaluated the effects of 
intermediary metabolites and electron transport inhibitors 
on the paralyzing effects of chloroquine on  B. pahangi and 
 O. volvulus . Their results suggested that chloroquine may 
inhibit aerobic energy metabolism in the filariae, possibly at 
the level of electron transport. 63 Unfortunately, these studies 
were not continued. 
 We also think that despite the lack of effect obtained in the 
present study with artesunate, it would also be worth consid-
ering artemisinin-derived compounds for future trials against 
filariae. This suggestion is justified because artemisinin reacts 
with translationally controlled tumor protein (TCTP) in 
 Plasmodium spp., 64 and homologs of TCTP are also present in 
 S. mansoni , 65  B. malayi , and  W. bancrofti . 66 
 As mass distribution of ivermectin extends progressively 
to cover all areas endemic for onchocerciasis, the probabil-
ity of observing post-ivermectin SAEs is decreasing because 
most people living in these foci and at risk would have already 
taken this drug at least once. Nonetheless, ivermectin is soon 
to be distributed outside these areas as part of the lymphatic 
filariasis elimination program. Even if the geographic distribu-
tion of lymphatic filariasis in central Africa is not well known, 
it is likely that many areas are co-endemic with loiasis. For this 
reason, research should continue to identify a drug able to 
progressively reduce high  L. loa microfilarial loads. 
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